KR20160098257A - 세포독성 펩티드 및 그의 접합체 - Google Patents

세포독성 펩티드 및 그의 접합체 Download PDF

Info

Publication number
KR20160098257A
KR20160098257A KR1020167015935A KR20167015935A KR20160098257A KR 20160098257 A KR20160098257 A KR 20160098257A KR 1020167015935 A KR1020167015935 A KR 1020167015935A KR 20167015935 A KR20167015935 A KR 20167015935A KR 20160098257 A KR20160098257 A KR 20160098257A
Authority
KR
South Korea
Prior art keywords
alkyl
independently selected
mmol
nhc
rti
Prior art date
Application number
KR1020167015935A
Other languages
English (en)
Korean (ko)
Inventor
베른하르드 가이어스탄거
얀 그뤼네발트
웨이지아 오우
테츠오 우노
용친 완
싱 왕
윤호 진
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20160098257A publication Critical patent/KR20160098257A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A61K47/48438—
    • A61K47/48569—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167015935A 2013-12-17 2014-12-17 세포독성 펩티드 및 그의 접합체 KR20160098257A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917293P 2013-12-17 2013-12-17
US61/917,293 2013-12-17
PCT/US2014/070800 WO2015095301A2 (fr) 2013-12-17 2014-12-17 Peptides cytotoxiques et leurs conjugués

Publications (1)

Publication Number Publication Date
KR20160098257A true KR20160098257A (ko) 2016-08-18

Family

ID=52463118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015935A KR20160098257A (ko) 2013-12-17 2014-12-17 세포독성 펩티드 및 그의 접합체

Country Status (16)

Country Link
US (3) US9988420B2 (fr)
EP (2) EP3082877B1 (fr)
JP (2) JP6636925B2 (fr)
KR (1) KR20160098257A (fr)
CN (1) CN105899526A (fr)
AU (1) AU2014364812B2 (fr)
BR (1) BR112016012538A2 (fr)
CA (1) CA2930614A1 (fr)
EA (1) EA201691251A1 (fr)
ES (1) ES2758506T3 (fr)
IL (1) IL245558B (fr)
MX (1) MX2016007865A (fr)
PL (1) PL3082877T3 (fr)
PT (1) PT3082877T (fr)
SG (1) SG11201604877UA (fr)
WO (1) WO2015095301A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2953976T3 (pl) * 2013-02-08 2021-11-02 Novartis Ag Specyficzne miejsca modyfikowania przeciwciał dla wytwarzania immunokoniugatów
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
MX2016008444A (es) 2013-12-27 2017-01-11 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de farmacos.
JP6615115B2 (ja) 2013-12-27 2019-12-04 ザイムワークス インコーポレイティド Ｖａｒ２ｃｓａ−薬物コンジュゲート
EP3129407A2 (fr) * 2014-03-12 2017-02-15 Novartis Ag Sites spécifiques utilisables pour la modification d'anticorps en vue de l'obtention d'immunoconjugués
KR20170016479A (ko) 2014-06-13 2017-02-13 노파르티스 아게 아우리스타틴 유도체 및 그의 접합체
EP3194421B1 (fr) 2014-09-17 2021-11-03 Zymeworks Inc. Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3455241B1 (fr) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Procédé de nettoyage et/ou de désinfection d'une matrice de séparation
WO2017194592A1 (fr) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Procédé de conservation d'une matrice de séparation
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
TW202014209A (zh) * 2018-06-20 2020-04-16 瑞士商諾華公司 用於消融造血幹細胞之抗體藥物軛合物
CN113365969B (zh) * 2018-11-23 2023-09-15 上海药明合联生物技术有限公司 含有邻苯二甲醛的连接体及其用于制备抗体-药物缀合物的用途
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
KR20230133289A (ko) * 2021-01-18 2023-09-19 아지노모토 가부시키가이샤 화합물 또는 이의 염, 및 이들에 의해 얻어지는 항체
WO2023061405A1 (fr) * 2021-10-12 2023-04-20 成都科岭源医药技术有限公司 Conjugué lieur-médicament ciblé hautement stable
US20240108744A1 (en) * 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
ATE190983T1 (de) 1991-08-09 2000-04-15 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
JP3469580B2 (ja) 1993-10-01 2003-11-25 帝国臓器製薬株式会社 新規なペプチド誘導体
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2150664T3 (es) 1995-04-21 2000-12-01 Teikoku Hormone Mfg Co Ltd Nuevos derivados peptidos.
CA2293632C (fr) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP3120861B1 (fr) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Composés intermédiaires pour la préparation de conjugués d'auristatin avec des éléments de liaison
ES2715776T3 (es) * 2004-11-12 2019-06-06 Seattle Genetics Inc Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N
EP1817341A2 (fr) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Anticorps et immunoconjugues mis au point
BRPI0612529A2 (pt) 2005-06-20 2010-11-23 Psma Dev Company Llc conjugados de anticorpo-medicamento de psma
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (fr) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Conjugués anticorps-médicament modifiés
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
CA2702555A1 (fr) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Agents de liaison au cd19 et utilisations de ceux-ci
ES2647927T3 (es) 2008-03-18 2017-12-27 Seattle Genetics, Inc. Conjugados enlazadores del fármaco auriestatina
ES2553874T3 (es) 2010-09-29 2015-12-14 Seattle Genetics, Inc. N-Carboxialquil-auristatinas y su uso
CA2815363C (fr) 2010-10-22 2020-07-14 Seattle Genetics, Inc. Effets synergiques entre des conjugues d'anticorps et de medicament a base d'auristatine et des inhibiteurs de la voie pi3k-akt-mtor
DK2678037T3 (en) 2011-02-25 2015-03-09 Lonza Ag Branched linker for protein pharmaceutical conjugates
CN103764667B (zh) 2011-03-16 2017-06-20 西雅图基因公司 N‑羧烷基耳他汀类及其应用
KR20140122649A (ko) 2011-04-21 2014-10-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (ADCs) 및 그의 용도
ES2690993T3 (es) 2011-05-27 2018-11-23 Ambrx, Inc. Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos
PL3327027T3 (pl) 2011-11-17 2021-06-28 Pfizer Inc. Cytotoksyczne peptydy i ich koniugaty przeciwciało lek
CA2859755C (fr) * 2011-12-23 2021-04-20 Pfizer Inc. Regions constantes d'anticorps modifies pour conjugaison specifique a un site, et leurs procedes et utilisations
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
PL2953976T3 (pl) 2013-02-08 2021-11-02 Novartis Ag Specyficzne miejsca modyfikowania przeciwciał dla wytwarzania immunokoniugatów

Also Published As

Publication number Publication date
EP3082877B1 (fr) 2019-08-28
PT3082877T (pt) 2019-12-03
SG11201604877UA (en) 2016-07-28
JP6636925B2 (ja) 2020-01-29
ES2758506T3 (es) 2020-05-05
BR112016012538A2 (pt) 2017-09-26
AU2014364812B2 (en) 2017-05-25
EA201691251A1 (ru) 2016-11-30
US9988420B2 (en) 2018-06-05
MX2016007865A (es) 2017-01-11
JP2020023514A (ja) 2020-02-13
WO2015095301A2 (fr) 2015-06-25
IL245558B (en) 2020-01-30
WO2015095301A3 (fr) 2015-09-03
EP3753578A1 (fr) 2020-12-23
US10392421B2 (en) 2019-08-27
JP2017503777A (ja) 2017-02-02
US20180244717A1 (en) 2018-08-30
US10787480B2 (en) 2020-09-29
AU2014364812A1 (en) 2016-07-07
US20190382441A1 (en) 2019-12-19
CN105899526A (zh) 2016-08-24
IL245558A0 (en) 2016-06-30
PL3082877T3 (pl) 2020-02-28
US20160311853A1 (en) 2016-10-27
CA2930614A1 (fr) 2015-06-25
EP3082877A2 (fr) 2016-10-26

Similar Documents

Publication Publication Date Title
US10787480B2 (en) Cytotoxic peptides and conjugates thereof
US10280139B2 (en) Cytotoxic peptides and conjugates thereof
US10912841B2 (en) Antibody-drug-conjugate and its use for the treatment of cancer
JP6498773B2 (ja) ベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
JP2018502131A (ja) ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
EP3215519A1 (fr) Dérivés d'amatoxine et leurs conjugués comme inhibiteurs de l'arn polymérase
JP2018528161A (ja) Ｋｓｐ阻害剤との部位特異的均一複合体
TW201836645A (zh) 具有酵素可裂解基團的細胞毒性藥劑之前藥
WO2017191579A1 (fr) Dérivés d'amatoxine et leurs conjugués à utiliser en tant qu'inhibiteurs de l'arn polymérase
JP2022533215A (ja) 親水性基を含むリンカーを有する抗体薬剤コンジュゲート
JP7023933B2 (ja) セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
EP3856258A1 (fr) Lieurs à base de sulfomaléimide et conjugués correspondants
KR20240067085A (ko) 항체 약물 접합체에 사용하기 위한 링커

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E601 Decision to refuse application